search
Back to results

Virtual Exercise for Multiple Myeloma (MY-PROGRESS)

Primary Purpose

Multiple Myeloma

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Exercise
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Multiple Myeloma focused on measuring exercise, pilot, feasibility

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. 18 years of age and older
  2. Diagnosis of multiple myeloma
  3. In one of the following three treatment categories:

    • Transplant ineligible patients, currently in first line treatment
    • Transplant eligible patients, sufficiently recovered from transplantation (>3 months following transplantation)
    • Patients with relapsed/recurrent myeloma with either 1-3 prior lines of treatment or 4+ prior lines
  4. Able to provide informed written consent in English
  5. Approved for physical activity participation by their oncologist and cleared for physical activity by the Certified Exercise Physiologist on the PAR-Q+

Exclusion Criteria:

  1. Unstable cardiac/metabolic condition that would be deemed unsafe to exercise
  2. Severe anemia
  3. Spinal instability requiring surgical intervention
  4. AL amyloidosis, solitary plasmacytoma, or Waldenstrom macroglobulinemia
  5. Too frail to participate in home exercise, as determine by baseline physical assessment (i.e., unable to complete a single sit-to-stand or balance on one foot for ≥ 3 seconds).
  6. Inability to provide consent
  7. Inability to commit to, and/or comply with the intervention due to personal reasons (e.g. vacation planned during the intervention period)

Sites / Locations

  • University of Alberta/ Cross Cancer Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Behavioural: Exercise

Arm Description

Participants will take part in a twelve week resistance and aerobic exercise program twice per week delivered virtually. Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises

Outcomes

Primary Outcome Measures

Feasibility (Adherence)
The percentage of total exercise dose prescribed that was actually completed (%)

Secondary Outcome Measures

Feasibility (Recruitment rate)
The number of participants recruited per month over the recruitment period and the proportion of patients who participate in the study, out of the total number of eligible patients
Feasibility (Completion rate)
The number of participants who completed the program and follow-up assessment out of the number of participants who consented to the study
Feasibility (Safety)
The number of adverse events reported by the participants during program participation, including the 12-week program and fitness assessments

Full Information

First Posted
July 21, 2020
Last Updated
September 16, 2021
Sponsor
University of Alberta
search

1. Study Identification

Unique Protocol Identification Number
NCT04484714
Brief Title
Virtual Exercise for Multiple Myeloma
Acronym
MY-PROGRESS
Official Title
Feasibility of a Virtually Supported Home-Based Resistance and Aerobic Exercise Program for Cancer Survivors With Multiple Myeloma
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
September 15, 2020 (Actual)
Primary Completion Date
June 15, 2021 (Actual)
Study Completion Date
August 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this pilot study is to determine the safety and feasibility a 12-week virtually supported home-based aerobic and resistance exercise program progressing cancer survivors with Multiple Myeloma to meet standards identified in the 2019 Exercise Guidelines for Cancer Survivors. The protocol will be measuring recruitment, adherence, completion, cost tracking, as well as fitness and quality of life outcomes. The study will be a single-group prospective before and after study that will help inform a future larger-scale project. We will aim to recruit 25 participants. The Health Research Ethics Board of Alberta Cancer Committee will approve this study. Participants will participate in a combined resistance and aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supported and progressive in nature, between 40 and 75 minutes each. Analyses: fitness testing and quality of life scales will be administered before and after the intervention. Scores will be compared to evaluate changes over the course of the intervention. Safety and feasibility information will be collected throughout the study and evaluated to determine program feasibility. Program satisfaction will be evaluated using a satisfaction survey.
Detailed Description
Multiple myeloma (MM), a cancer of the plasma cells in bone marrow, is associated with osteolytic bone destruction, leading to deformities, chronic pain, reduced mobility and functioning, fatigue, and risk of fracture. Although incurable, newly developed therapies are extending survival, but some with significant side-effects. Patients may be living longer but with lasting, debilitating side-effects. Exercise has been proposed as a way to optimize patient function and quality of life in the face of lasting symptom burden. However, current evidence-informed exercise guidelines for cancer survivors may not be appropriate for those with bone fragility, including those with MM, as they are based on findings from studies in breast and prostate cancers. In MM specifically, the literature presents mixed results, and several studies have limited generalizability, reproducibility, or were underdosed. The main objective of this study is to determine the safety and feasibility of a 12-week virtually supported home-based aerobic and resistance exercise program that aims to progress individuals to the 2019 Exercise Guidelines for Cancer Survivors in a sample of cancer survivors with multiple myeloma, as defined by: Recruitment rate: ≥ 21 participants consenting to the study over a 7-month recruitment period (primary endpoint) Completion rate: ≥ 80% of participants consenting to the study complete the 12-week assessment Safety: no increase in the rate of bony events above those estimated to occur in the target population Adherence: average completion of ≥ 75% of the exercise prescription amongst participants We will aim to recruit 25 participants from clinics at the local cancer hospital, the local disease-group support society, and from the currently accruing Alberta Cancer Exercise program. Subjects will be screened for eligibility and if they meet all eligibility criteria, an information letter of the study will be provided, and they will be asked to contact the investigators if interested in taking part in the study. All participants will be required to provide written informed consent as per the Health Research Ethics Board of Alberta: Cancer Committee (HREBA). Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises. Analyses: Demographic and medical information will be presented using median and range and percentage for interval and nominal data, respectively. Descriptive statistics (mean ± SD and frequencies) will be used to report safety and feasibility measures. Adherence will be tracked as the percentage of total training load prescribed that was actually completed. Wilcoxon Signed Rank Tests will be used to compare and pre- and post-intervention fitness assessment and quality of life scores. All analyses will be conducted using Stata/MP (version 13.0, StataCorp LLC, College Station, TX), with alpha set to 0.05.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
exercise, pilot, feasibility

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single group before and after
Masking
None (Open Label)
Allocation
N/A
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Behavioural: Exercise
Arm Type
Experimental
Arm Description
Participants will take part in a twelve week resistance and aerobic exercise program twice per week delivered virtually. Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises
Intervention Type
Behavioral
Intervention Name(s)
Exercise
Intervention Description
Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.
Primary Outcome Measure Information:
Title
Feasibility (Adherence)
Description
The percentage of total exercise dose prescribed that was actually completed (%)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Feasibility (Recruitment rate)
Description
The number of participants recruited per month over the recruitment period and the proportion of patients who participate in the study, out of the total number of eligible patients
Time Frame
7 months
Title
Feasibility (Completion rate)
Description
The number of participants who completed the program and follow-up assessment out of the number of participants who consented to the study
Time Frame
12 weeks
Title
Feasibility (Safety)
Description
The number of adverse events reported by the participants during program participation, including the 12-week program and fitness assessments
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Home-based Stepping Test
Description
Change in 2-minute stepping test (number of steps)
Time Frame
Change from baseline to 12 weeks
Title
Shoulder flexibility
Description
Change in active shoulder flexion range of motion (degrees)
Time Frame
Change from baseline to 12 weeks
Title
Lower Body Flexibility
Description
Change in sit-and-reach test (cm)
Time Frame
Change from baseline to 12 weeks
Title
Leg Strength
Description
Change in 30-second sit-to-stand (number of repetitions)
Time Frame
Change from baseline to 12 weeks
Title
Balance
Description
Change in one legged stance test (seconds
Time Frame
Change from baseline to 12 weeks
Title
Balance Confidence
Description
Activities-specific Balance Confidence (ABC) scale (score)
Time Frame
Change from baseline to 12 weeks
Title
Upper Extremity Function
Description
Change in Upper Extremity Functional Index (score)
Time Frame
Change from baseline to 12 weeks
Title
Lower Extremity Function
Description
Change in Lower Extremity Functional Scale (score)
Time Frame
Change from baseline to 12 weeks
Title
Cancer-Specific Quality of Life
Description
Change in Functional Assessment of Cancer Therapy General, Multiple Myeloma, and Bone Pain Scales (score)
Time Frame
Change from baseline to 12 weeks
Title
Fatigue
Description
Change in FACIT-Fatigue Subscale (score)
Time Frame
Change from baseline to 12 weeks
Title
Six-minute walk test (optional)
Description
Six-minute walk test distance (metres)
Time Frame
Change from baseline to 12 weeks
Title
Upper Extremity Grip Strength (optional)
Description
Hand-grip dynamometry (kg)
Time Frame
Change from baseline to 12 weeks
Title
Upper extremity strength (optional)
Description
One repetition maximum bench press (kg)
Time Frame
Change from baseline to 12 weeks
Title
Lower extremity strength (optional)
Description
One repetition maximum leg press (kg)
Time Frame
Change from baseline to 12 weeks
Title
Core Endurance (optional)
Description
Plank hold (seconds)
Time Frame
Change from baseline to 12 weeks
Title
Fall risk (optional)
Description
Three-metre backwards walk test (seconds)
Time Frame
Change from baseline to 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age and older Diagnosis of multiple myeloma In one of the following three treatment categories: Transplant ineligible patients, currently in first line treatment Transplant eligible patients, sufficiently recovered from transplantation (>3 months following transplantation) Patients with relapsed/recurrent myeloma with either 1-3 prior lines of treatment or 4+ prior lines Able to provide informed written consent in English Approved for physical activity participation by their oncologist and cleared for physical activity by the Certified Exercise Physiologist on the PAR-Q+ Exclusion Criteria: Unstable cardiac/metabolic condition that would be deemed unsafe to exercise Severe anemia Spinal instability requiring surgical intervention AL amyloidosis, solitary plasmacytoma, or Waldenstrom macroglobulinemia Too frail to participate in home exercise, as determine by baseline physical assessment (i.e., unable to complete a single sit-to-stand or balance on one foot for ≥ 3 seconds). Inability to provide consent Inability to commit to, and/or comply with the intervention due to personal reasons (e.g. vacation planned during the intervention period)
Facility Information:
Facility Name
University of Alberta/ Cross Cancer Institute
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2G4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
No plan in place at this time

Learn more about this trial

Virtual Exercise for Multiple Myeloma

We'll reach out to this number within 24 hrs